Susceptibility may be the key, says ViroLogic:
This article was originally published in Clinica
Executive Summary
After years spent studying HIV drug resistance, ViroLogic now believes that the opposite phenomenon, viral hypersusceptibility, may offer a way to improve treatment for HIV-infected patients. In a retrospective study of 30 treatment-experienced patients published in AIDS (June 15th), ViroLogic researchers found that the reduction in viral load following treatment with non-nucleoside reverse transcriptase inhibitors (NNRTIs) was 20 times higher in patients with virus that was hypersusceptible to NNRTIs, and no resistance-related mutations, than in those with virus showing normal sensitivity to the drugs. Viral sensitivity was determined using the South San Francisco, California company's PhenoSense HIV drug resistance assay.
You may also be interested in...
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.
‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation
CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.